Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Viewpoint - Terns Pharmaceuticals, Inc. is actively participating in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, showcasing its commitment to addressing serious diseases through its clinical-stage biopharmaceutical portfolio [1]. Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases, particularly in oncology and obesity [3]. - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort prioritizing a GIPR antagonist nomination candidate [3]. Event Details - Senior management from Terns Pharmaceuticals will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 4:00 p.m. ET [1]. - A live webcast of the event will be available on the investor relations page of Terns Pharmaceuticals' website, with a replay archived for at least 30 days [2].